Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Core Insights - Takeda had a successful year in 2025, with three new molecular entities (NMEs) achieving positive Phase III readouts: rusfertide, oveporexton, and zasocitinib [2] - The company is preparing for the launch of these drugs and is also experiencing a maturing in-line portfolio [2] - A new CEO is set to join in June, prompting discussions on the future direction of the company [2]